Prostate cancer is the second most common and the sixth deadliest male cancer worldwide.1 In the UK, 43% of men present with low- and intermediate-risk localised disease,2 for which level 1 evidence suggests non-inferiority of active surveillance (AS) to radical treatment in terms of 10-year survival.3,4